Apexigen, Inc. - Common Stock APGN 深 沪
已收盘 08-23 16:00:00 美东时间
0.3851
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.3851
- 总市值 957.43万
- 52周最高 8.28
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.3305
- 委 比 0.00%
- 总股本 2486.19万
- 历史最高 31.35
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.3305
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
波士顿2025年12月18日讯，Pyxis Oncology宣布其研究药物micvotabart pelidotin（MICVO）在治疗复发/转移性头颈部鳞癌（R/M HNSCC）的早期临床试验中取得积极结果。作为单药治疗，在5.4 mg/kg剂量下，显示出46%的确认客观缓解率（ORR）和92%的疾病控制率（DCR）；在与Keytruda（pembrolizumab）联合治疗中，ORR达71%，DCR为100%。两项研究均展现出良好的耐受性。公司计划于2026年中和下半年分别公布单药及联合用药的最新数据。
12-18 12:00
89bio names Francis Sarena as COO
89bio (NASDAQ:ETNB) said it has appointed Francis Sarena as COO, effective August 5. Sarena has over two decades of experience, and served as COO and president at Apexigen before joining ETNB. More on...
2024-08-07 20:25
Pyxis Oncology gets $8M payment for sale pf royalty rights
Pyxis Oncology (NASDAQ:PYXS) said it has completed the sale of its rights to royalties from the commercialization of Beovu and another asset to Novartis for a one-time cash payment of $8 million. The ...
2024-03-27 19:43
先聲藥業(02096.HK)注射用蘇維西塔單抗新藥上市申請獲受理
先聲藥業(02096.HK)公布，注射用蘇維西塔單抗新藥上市申請獲中國國家藥品監督管理局受理，適應症為蘇維西塔單抗聯合化療用於含鉑化療治療失敗的復發性卵巢癌、輸...
2024-03-17 20:18
先声药业(02096.HK)：注射用苏维西塔单抗新药上市申请获国家药品监督管理局受理
格隆汇3月15日丨先声药业(02096.HK)公告，2024年3月15日，注射用苏维西塔单抗新药上市申请获中国国家药品监督管理局(NMPA)受理，适应症为苏维西...
2024-03-15 21:16
当Biotech迎来中年危机
“并购*”丹纳赫再次出手：8月28日，丹纳赫集团宣布与全球*的蛋白质耗材供应商Abcam达成协议，以每股24美元的现金收购Abcam的所有流通股，交易总价或达到...
2023-08-31 10:47
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers HeartBeam (NASDAQ:BEAT) stock rose 20.1% to $2.42 during Thursday's pr...
2023-05-25 21:07
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNL, RTL, APGN
NEW YORK, May 24, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or ...
2023-05-25 00:37
Pyxis Oncology Bolsters Oncology Portfolio Through $16M Apexigen Acquisition
Pyxis Oncology (NASDAQ:PYXS) has announced an acquisition of Apexigen (NASDAQ:APGN) that is expected to be completed in the second half of 2023.
2023-05-25 00:19
